Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

CEA and ferritin were determined in 90 subjects with the aim of comparing their value in the diagnosis of pancreatic malignancy. Ferritin was shown to be more sensitive than CEA in detecting pancreatic cancer patients (68.4% and 57.9%, respectively) all of whom were, however, in an inoperable stage. In contrast, CEA showed a higher specificity as compared to ferritin (77.4% and 47.2%, respectively), the latter being frequently increased in inflammatory conditions such as chronic pancreatitis. The simultaneous assessment of CEA and ferritin showed the highest sensitivity when either parameter was found to be pathological and the highest specificity when both were. The receiver-operating characteristic curves demonstrated that CEA is more discriminating than ferritin for all serum values. Neither ferritin nor CEA may be considered a practically suitable marker of pancreatic cancer.
 ...
PMID:CEA and ferritin in chronic pancreatic disease: a comparative evaluation. 401 9

Screening for pancreatic cancer was carried out by serum pancreatic oncofetal antigen (POA) tests in 440 out-patients with abdominal complaints, with concomitant assay of carcinoembryonic antigen, alpha-fetoprotein and ferritin. POA was positive in 13 patients, of whom 3 cases of pancreatic cancer, and 4 of other malignant diseases were diagnosed while the remaining 6 were non-malignant. Of these out-patients, 5 cases were finally diagnosed as having pancreatic cancer by further examinations. Of these 5 patients, POA was negative in 2, of whom one was positive for CEA and AFP. Accordingly, when POA test was applied concomitantly with the other 3 marker tests, the detection rate of pancreatic cancer was elevated to 4/5. Twenty-three patients were found to have malignant diseases and 20 of them were positive for at least one of the 4 markers tested. These results suggest that serum POA assay is useful for screening the pancreatic cancer, especially when the other tumor markers are assayed concomitantly.
 ...
PMID:Serum pancreatic oncofetal antigen: its clinical usefulness for screening pancreatic cancer in combination with tests for other tumor markers. 619 38

We succeeded in an establishment of a human pancreatic cancer cell line (PK-1) from liver metastasis of pancreatic cancer. Primary pancreatic cancer cells grew as islands surrounded by fibroblastic cells. However, these fibroblastic cells were gradually omitted by the polygonal shaped cancer cells. This cell line contained neither zymogen granules nor trypsin indicating that this pancreatic cancer originated from pancreatic duct cells. Modal chromosome numbers of this cell line were 42 and 72 and the doubling time was 48 hr. This cell line was transplantable in athymic nude mice to form progressive tumors which had histology similar to that of the original cancer (papillotubular adenocarcinoma). Neither AFP nor ferritin but CEA was detected on the surface and in the cytoplasm of this cell line in indirect immunofluorescence. Rabbit antiserum against this pancreatic cancer cell line detected pancreatic cancer associated antigen besides CEA in the culture supernatant. This antiserum reacted with sera from patients with pancreatic cancer to form a distinct precipitin line in agarose gel which fused with the precipitin line formed between the culture supernatant of this cell line and the antiserum.
 ...
PMID:Establishment of a human pancreatic cancer cell line and detection of pancreatic cancer associated antigen. 620 69

Pancreatic oncofetal antigen (POA) is considered to be an oncofetal antigen for human pancreas, and its measurement seems to be useful in the diagnosis of pancreatic cancer. In this study, POA, CEA, ferritin, BMG (beta 2 microglobulin) and AFP either in sera in pancreatic juice were measured in patients with pancreatic cancer, chronic pancreatitis and other various diseases, and their diagnostic value was comparatively evaluated. POA showed the highest sensitivity for pancreatic cancer compared with CEA or others. POA and CEA in pancreatic juice showed higher sensitivity and specificity than those in serum, probably reflecting the earlier malignant status. Localization of POA was immunohistochemically observed in tissues of pancreatic cancer and fetal pancreas. In some cases of pancreatic cancer with elevated serum CEA, ferritin and BMG, only CEA was positive in cancer cells, indicating that CEA is produced from cancer cells while ferritin and BMG are not produced from them. The combined assay of POA and CEA improved sensitivity for the diagnosis of pancreatic cancer. It is concluded that POA could be a useful tumor marker providing valuable information in the clinical diagnostic system of pancreatic cancer.
 ...
PMID:[Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer]. 634 42

In 116 subjects, serum ribonuclease (RNase) and ferritin were determined in order to evaluate whether their combined evaluation might improve the diagnostic accuracy of each test. Significantly higher levels were found in pancreatic cancer patients both for RNase and ferritin than in control subjects and chronic pancreatitis. Sensitivity and specificity in diagnosing pancreatic cancer were 86% and 46%, respectively for RNase; 76% and 65% for ferritin. One of the two tests was pathological in 100% of pancreatic cancer, with a specificity of 29.9%; both were pathological in 62.1%, with a specificity of 82.1%. The results emphasize the limits of the combined assessment of pancreatic cancer markers.
 ...
PMID:Combined evaluation of serum ribonuclease and ferritin: any advantages in pancreatic cancer diagnosis? 650 93

An oncofetal pancreatic antigen (OPA) has been identified and purified from the blood of patients with pancreatic cancer. Characterisation studies on OPA have shown that it is a protein of molecular weight 40 000 with alpha2 electrophoretic mobility. OPA is clearly different from alpha-fetoprotein, carcinoembryonic antigen, ferritin, acute phase reactants, and normal serum proteins. A rocket immunoassay has been developed allowing the quantitation of OPA in serum; it has been applied to samples from over 700 individuals with a variety of conditions. Elevated levels of OPA have been found in 42 of 48 (88%) patients with biopsy-proven pancreatic cancer and in a much smaller percentage of patients with other cancers or with other conditions considered in the differential diagnosis of pancreatic cancer. The studies indicate that serum OPA measurements may be useful as a preliminary screening test for pancreatic cancer and for monitoring the course of the disease.
 ...
PMID:Partial characterisation of an oncofetal pancreatic antigen. Its role in the differential diagnosis and therapy of patients with pancreatic cancer. 702 32

Serum ferritin, described as increased in patients with pancreatic cancer, was studied in 109 subjects by an immunoradiometric technique in order to assess its reliability in detecting pancreatic malignancy. A significant increase of serum ferritin was found in pancreatic cancer as compared to controls (p less than 0.01), to calcifying (p less than 0.05), non-calcifying (p less than 0.05), and recurrent (p less than 0.01) chronic pancreatitis. Nevertheless, high levels of serum ferritin were found in 10 out of the 36 chronic pancreatitis patients and in 10 out of the 26 patients with non-pancreatic diseases, whilst values within the normal range were detected in 6 out of the 22 pancreatic cancer patients. These data suggest that serum ferritin, although frequently increased in pancreatic cancer, cannot be considered a marker of pancreatic malignancy.
 ...
PMID:Serum ferritin in pancreatic disease. An accurate test of malignancy? 716 9

Serum ferritin levels were measured in 72 normal subjects and in 214 cases with various diseases by an immunoradiometric assay. In normal subjects, the serum ferritin levels were 27-230 mg/ml. Elevated serum ferritins were observed in most cases with iron excess and acute hepatitis. Markedly elevated levels were found in the majority of cases with acute leukemia, malignant lymphoma, hepatoma, and pancreatic cancer. High ferritin levels were also found in other malignant diseases. However, the range overlapped broadly with that of nonmalignant diseases. The serum ferritin correlated significantly with serum iron in normals and in those with iron deficiency anemia. In most nonmalignant cases, the serum ferritin and iron levels distributed on a regression line obtained from levels in normals and those with iron deficiency anemia. However, 92% of the malignant cases showed a serum ferritin to iron ratio higher than that of normal subjects. The estimation of the serum ferritin to iron ratio is a useful means for screening patients or in the differential diagnosis of a suspected malignant lesion.
 ...
PMID:Clinical evaluation of serum ferritin to iron ratio in malignant diseases. 725 Jan 41

Studies on the purification, characterization and clinical application of pancreatic oncofetal antigen were reported. This antigen was purified from fetal pancreas, and migrated in the beta-region on electrophoresis. Its molecular weight was about 80 x 10(4) daltons on gel filtration with a Sephacryl S-300. This antigen is clearly different from other oncofetal antigens such as alfafetoprotein, carcinoembryonic antigen or ferritin. Clinically, this pancreatic oncofetal antigen was positive in sera of 68.4% of the patients with pancreatic cancer. However, elevated level of this antigen was also observed in the sera of some patients with biliary tract cancer, colon cancer or gastric cancer. The antigen was also found in pancreatic juice obtained from patients with pancreatic cancer in almost the same incidence as in their sera. It is suggested that a pancreatic oncofetal antigen assay of sera and pancreatic juice in combination with other oncofetal antigens is valuable for the diagnosis and monitoring the clinical course of pancreatic cancer.
 ...
PMID:A pancreatic oncofetal antigen: its partial purification and clinical application. 726 7

Serum ferritin H and L subunit levels and H/L ratios were evaluated in normal subjects and patients with various diseases by means of enzyme-linked immunosorbent assay using monoclonal antibody against ferritin H or L subunits. In normal subjects, serum levels of H subunit were significantly lower than those of L subunit, as previously reported by Cazzola and coworkers. Although the serum levels of L subunit were elevated and the values of H/L ratios were decreased in inflammatory diseases, serum levels of H subunit were remarkably high in patients with infectious mononucleosis. In liver disease, elevation of mean values of L subunit was observed. However, in liver cirrhosis and severe acute hepatitis, the serum levels of H subunit were often elevated as well as those of L subunit, and so it was suggested that the elevation of H subunit was related to the degree of hepatocellular injury. In hepatocellular carcinoma and pancreatic cancer, since the levels of H/L ratio were higher than controls and no correlation was observed between H and L subunits, it was suggested that the production of H subunit was increased in these cancers. However, the result of H/L ratio determination in serum ferritin did not appear enough to be important for tumor marker, because of a few instances demonstrated over the cut off limit of H/L ratio in neoplastic diseases. The rate of the patients whose H or L subunit levels were over the cut off point was higher in leukemia than in solid cancer, and so it was likely that the measurement of H and L subunit at the same time was clinically useful in leukemic patients. In acute myeloblastic leukemia, relatively high levels of serum L subunits and low H/L ratio were shown. It was suggested that the measurement of H and L subunits in patients with neoplastic diseases would also be useful for monitoring the effect of the therapy.
 ...
PMID:[Clinical significance of serum ferritin H and L subunit determination in various diseases--evaluation by enzyme-linked immunosorbent assay]. 795 82


<< Previous 1 2 3 Next >>